Compound · clinical trials

Anastrozole clinical trials

Also listed in trial records as Anastrazole, Arimidex, ICI D1033, ZD-1033, Anastrozol

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 43 trials in our France, Mexico, Italy, USA, Spain, Canada, Israel, South Korea, Germany, Belgium, China, Taiwan, Australia, Brazil, Portugal, UK, Turkey, Japan, Poland, Netherlands, India, Austria, Ireland, Czechia, Switzerland, Singapore, Sweden, Denmark and Norway registers that name Anastrozole as an intervention. Synced 9 Nov 2026

43Current trials

14Recruiting now

27Lead sponsors

29Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 9 Nov 2026 · Editorial standards

At a glance

Anastrozole is named as an intervention in 43 current clinical trials in our France, Mexico, Italy, USA, Spain, Canada, Israel, South Korea, Germany, Belgium, China, Taiwan, Australia, Brazil, Portugal, UK, Turkey, Japan, Poland, Netherlands, India, Austria, Ireland, Czechia, Switzerland, Singapore, Sweden, Denmark and Norway registers. 14 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Eli Lilly and Company (7). The most-studied condition is Breast Cancer. The EU clinical trials register (CTIS) separately lists 3 authorised or ongoing trials.

Where Anastrozole is approved

All regulators →

Of the three regulators tracked here, the first to approve Anastrozole was the US, on 27 Dec 1995. It is approved in 2 of the 3 regulators tracked here.

USUnited States (FDA)

27 Dec 1995

Arimidex

NDA020541 on Drugs@FDA

First original NDA/BLA approval

EUEuropean Union (EMA)

No centralised EU authorisation (it may be authorised nationally)

First centralised authorisation

CACanada (Health Canada)

1 Aug 1996

Arimidex

Notice of Compliance 4204

First new-drug NOC

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

What health systems spend on Anastrozole

All medicines →

ENNHS England

£1.0m

509,077 items dispensed, Sep 2025 to Aug 2026

-12% on the previous 12 months

Net ingredient cost, community prescriptions

USUS Medicaid

$3.5m

230,818 prescriptions in 2025 · Anastrozole, Arimidex, Anastrozole

+3% on 2024

Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Anastrozole works

All drug targets →

Cytochrome P450 19A1 inhibitor Inhibitor
Target: CYP19A1 cytochrome P450 family 19 subfamily A member 1
✓ In ChEMBL and the Guide to Pharmacology

Other medicines acting on CYP19A1

Letrozole Exemestane

Diseases it has been tested for in clinical trials, by furthest phase

GynecomastiaPhase 3
InfertilityPhase 3
Klinefelter syndromePhase 3
Ductal breast carcinoma in situPhase 3
Insulin resistancePhase 2
Bone metastasisPhase 2
CancerPhase 2
Cardiovascular disorderPhase 2
Endometrial cancerPhase 2
Endometrial carcinomaPhase 2

32 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1399, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 5137, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

NICE appraisals of Anastrozole

All NICE appraisals →

NICE, which decides whether the NHS in England should fund new medicines, has published 1 technology appraisal of Anastrozole. 1 is current, and 1 of it recommends it for at least some patients.

Appraisal	NICE recommendation	Published	Status
Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer NICE TA112	Recommended	22 Nov 2006	Current

NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Patient leaflets for Anastrozole

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

IE
Ireland: 10 products on the HPRA list
Each product record links to the HPRA, which publishes the leaflet and SmPC.
UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Reference identifiers for Anastrozole

ATC code: L02BG03
ChEMBL: CHEMBL1399
DrugBank: DB01217
PubChem CID: 2187
CAS number: 120511-73-1
FDA UNII: 2Z07MYW1AZ
Wikidata: Q419143
Wikipedia: Anastrozole

Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.

Trials by status

Recruiting1433%
Not yet open25%
Active, closed2660%
By invitation12%

Trials by phase

Phase 32967%
Phase 2716%
Phase 137%
Phase 1/225%
Phase 412%
Not applicable12%

Clinical trials of Anastrozole

43 trials

Study	Phase	Status	Lead sponsor	Registers
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) NCT05512364 · ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer	Phase 3	Recruiting	European Organisation for Research and Treatment of Cancer - EORTC	Ireland, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Switzerland, Portugal
Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome NCT05586802 · ClinicalTrials.gov ↗ · Klinefelter Syndrome	Phase 3	Recruiting	Georgios Papadakis	Switzerland
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy NCT05774951 · Breast Cancer, Early Breast Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) NCT05891093 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Recruiting	Fudan University	China
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer NCT06072781 · Low Grade Serous Ovarian Cancer	Phase 3	Recruiting	Verastem, Inc	Ireland, UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Canada, Japan, South Korea, Australia
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer NCT06380751 · Advanced Breast Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Poland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer NCT07024173 · ClinicalTrials.gov ↗ · Locally Advanced Breast Cancer, Metastatic Breast Cancer	Phase 3	Recruiting	Shandong Suncadia Medicine Co., Ltd	China
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) NCT07174336 · Breast Neoplasms, Neoplasm Metastasis	Phase 3	Recruiting	Eli Lilly and Company	Ireland, UK, USA, China, Germany, France, Spain, Italy, Belgium, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer NCT07349069 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Recruiting	Shandong Suncadia Medicine Co., Ltd	China
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial NCT07391774 · ClinicalTrials.gov ↗ · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8	Phase 3	Recruiting	National Cancer Institute (NCI)	Mexico, Israel
Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS) NCT03624244 · Low Grade Endometrial Stromal Sarcoma	Phase 2	Recruiting	Centre Leon Berard	France
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer NCT04985266 · ClinicalTrials.gov ↗ · ER+ Breast Cancer, HER2-negative Breast Cancer	Phase 2	Recruiting	Royal Marsden NHS Foundation Trust	France
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer NCT05467891 · ClinicalTrials.gov ↗ · Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer	Phase 2	Recruiting	Oana Danciu	Mexico
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors NCT05768139 · Breast Cancer, Solid Tumors, Adult	Phase 1/2	Recruiting	Eli Lilly and Company	Ireland, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Japan
Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer NCT06223698 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Not yet open	Region Örebro County	Sweden
The Role of Estrogen and Testosterone in Determining Brain Blood Flow and Metabolic Regulation in Humans NCT07212712 · ClinicalTrials.gov ↗ · Cerebral Blood Flow, Cerebral Blood Flow Regulation, Sex Differences	Not applicable	Not yet open	University of British Columbia	Canada
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study NCT05645536 · Breast Cancer	Phase 3	By invitation	Tolmar Inc	USA, India, Brazil, Mexico
Roll-over Study to Allow Continued Access to Ribociclib NCT05161195 · Metastatic Breast Cancer	Phase 4	Active, closed	Novartis Pharmaceuticals	USA, India, China, Spain, Italy, Poland, Portugal, Turkey, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) NCT00310180 · Breast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7	Phase 3	Active, closed	National Cancer Institute (NCI)	Ireland, Canada, Mexico, Australia, Israel
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer NCT01272037 · Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Ireland, France, Spain, Canada, Mexico, South Korea, Israel
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer NCT01674140 · Breast Cancer	Phase 3	Active, closed	SWOG Cancer Research Network	Mexico, Israel
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery NCT01953588 · ClinicalTrials.gov ↗ · Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma	Phase 3	Active, closed	Alliance for Clinical Trials in Oncology	Mexico, Israel
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer NCT02246621 · Breast Cancer	Phase 3	Active, closed	Eli Lilly and Company	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Austria, Turkey, Canada, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer NCT02763566 · Breast Cancer	Phase 3	Active, closed	Eli Lilly and Company	India, China, Brazil
CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer NCT02918084 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Active, closed	IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy	Italy
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer NCT02947685 · ClinicalTrials.gov ↗ · HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer	Phase 3	Active, closed	Alliance Foundation Trials, LLC	Germany, France, Spain, Italy, Portugal, Mexico, Australia
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer NCT03425838 · ClinicalTrials.gov ↗ · Breast Neoplasm Female	Phase 3	Active, closed	Borstkanker Onderzoek Groep	Netherlands
Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer NCT04158362 · ClinicalTrials.gov ↗ · Cancer Metastatic	Phase 3	Active, closed	UNICANCER	France
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease NCT04711252 · ER-Positive HER2-Negative Breast Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Mexico, Japan, South Korea, Taiwan
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer NCT04906395 · Breast Cancer	Phase 3	Active, closed	Tolmar Inc	USA, India, Canada, Brazil, Mexico
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) NCT04964934 · ER-Positive HER2-Negative Breast Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Austria, Norway, Portugal, Turkey, Canada, Japan, South Korea, Taiwan, Australia, Israel
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer NCT05514054 · Breast Neoplasms	Phase 3	Active, closed	Eli Lilly and Company	Ireland, UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) NCT05952557 · Breast Cancer, Early Breast Cancer	Phase 3	Active, closed	AstraZeneca	Ireland, UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer NCT06016738 · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer	Phase 3	Active, closed	Olema Pharmaceuticals, Inc	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Portugal, Canada, Brazil, Mexico, South Korea, Taiwan, Australia
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence NCT06492616 · Breast Cancer	Phase 3	Active, closed	Stemline Therapeutics, Inc	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, South Korea, Taiwan, Singapore, Australia, Israel
FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer NCT03944434 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Active, closed	Fondazione Sandro Pitigliani	Italy
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer NCT04569747 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer	Phase 2	Active, closed	Dana-Farber Cancer Institute	Israel
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer NCT06001762 · ClinicalTrials.gov ↗ · Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma	Phase 2	Active, closed	Dana-Farber Cancer Institute	Israel
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy NCT06957379 · ClinicalTrials.gov ↗ · HR+/HER2- Advanced/Metastatic Breast Cancer	Phase 2	Active, closed	CSPC ZhongQi Pharmaceutical Technology Co., Ltd	China
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast NCT03304080 · ClinicalTrials.gov ↗ · Breast Neoplasms, Breast Diseases	Phase 1/2	Active, closed	Icahn School of Medicine at Mount Sinai	Israel
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread NCT02057133 · Breast Neoplasms	Phase 1	Active, closed	Eli Lilly and Company	USA
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer NCT02779751 · Non Small Cell Lung Cancer, Breast Cancer	Phase 1	Active, closed	Eli Lilly and Company	USA, France, Spain, Italy, Belgium, Turkey, Taiwan
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer NCT04556773 · Metastatic Breast Cancer	Phase 1	Active, closed	AstraZeneca	USA, France, Belgium, Canada, Brazil, Mexico, South Korea, Taiwan, Australia

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Anastrozole in the EU trials register (CTIS)

3 trials

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Anastrozole. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.

Study	Phase	Status	Sponsor	Countries
Optimization of De-EscalatiON strategies in early breast cancer 2026-527524-27-00 · Neoplasms	Phase 2	Authorised	Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCS	Italy
Radium223 dichloride (223RaCl) in the treatment of symptomatic bone metastases from breast cancer. 2025-524208-31-00 · CTIS ↗ · Neoplasms	Phase 2	Authorised	Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone	Italy
NoELA_No Endocrine therapy in small HR+ HER2- low relapse risk Luminal A early breast cancer, a single-arm de-escalation trial 2025-523683-20-00 · CTIS ↗ · Neoplasms	Phase 2	Authorised	Unicancer	France

Anastrozole across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

10 single-substance products containing Anastrozole on the HPRA medicines list.

Agerdex 1 mg film-coated tabletsViatris Limited · PA23266/075/001 · Marketed
Amidex 1 mg film-coated tabletsClonmel Healthcare Ltd · PA0126/189/001 · Marketed
Anastrozole 1 mg film-coated tabletsAccord Healthcare Ireland Ltd. · PA2315/076/001 · Marketed
Anastrozole Teva 1 mg film-coated tabletsTeva Pharma B.V. · PA0749/028/001 · Marketed
Arimidex 1 mg film-coated tabletsLaboratoires Juvise Pharmaceuticals · PA23154/001/001 · Marketed

All 10 Irish products →

Supply shortages

No entry for Anastrozole in the EMA, FDA or German BfArM shortage lists we track.

EU shortages US shortages German shortages

Conditions studied with Anastrozole

51 conditions

Breast Cancer16 HER2-negative Breast Cancer4 Breast Neoplasms4 Metastatic Breast Cancer4Breast Cancer, Early Breast Cancer2ER-Positive HER2-Negative Breast Cancer2Advanced Breast Cancer2Breast Ductal Carcinoma In Situ1Invasive Breast Carcinoma1Multicentric Breast Carcinoma1Multifocal Breast Carcinoma1ER-positive Breast Cancer1

All 51 conditions

Condition (as registered)	Trials
Breast Cancer	16
HER2-negative Breast Cancer	4
Breast Neoplasms	4
Metastatic Breast Cancer	4
Breast Cancer, Early Breast Cancer	2
ER-Positive HER2-Negative Breast Cancer	2
Advanced Breast Cancer	2
Breast Ductal Carcinoma In Situ	1
Invasive Breast Carcinoma	1
Multicentric Breast Carcinoma	1
Multifocal Breast Carcinoma	1
ER-positive Breast Cancer	1
Stage IIB Breast Cancer	1
Stage III Breast Cancer	1
Neoplasm Metastasis	1
Low Grade Serous Ovarian Cancer	1
Solid Tumors, Adult	1
Breast Adenocarcinoma	1
Hormone Receptor Positive	1
Stage IA Breast Cancer AJCC v7	1
Stage IB Breast Cancer AJCC v7	1
ER Positive Breast Cancer	1
Non Small Cell Lung Cancer	1
HR+/HER2- Advanced/Metastatic Breast Cancer	1
Locally Advanced Breast Cancer	1
HER-2 Positive Breast Cancer	1
Estrogen Receptor Positive Breast Cancer	1
Cancer Metastatic	1
ER+ Breast Cancer	1
Breast Neoplasm Female	1
Klinefelter Syndrome	1
Cerebral Blood Flow	1
Cerebral Blood Flow Regulation	1
Sex Differences	1
Exercise	1
Anatomic Stage II Breast Cancer AJCC v8	1
Anatomic Stage IIIA Breast Cancer AJCC v8	1
Anatomic Stage IIIC Breast Cancer AJCC v8	1
Estrogen Receptor-Positive Breast Carcinoma	1
Locoregional Recurrence	1
Hormone Receptor-positive Breast Cancer	1
Estrogen Receptor-positive Breast Cancer	1
Invasive Ductal Breast Carcinoma	1
Invasive Lobular Breast Carcinoma	1
Breast Diseases	1
Early-stage Breast Cancer	1
High Risk Breast Carcinoma	1
HER2-positive Breast Cancer	1
Invasive Carcinoma of the Breast	1
Node Negative Breast Cancer	1
Low Grade Endometrial Stromal Sarcoma	1

By country register

Register	Trials	Recruiting
Clinical trials in France	20	8
Clinical trials in Mexico	18	3
Clinical trials in Italy	18	6
Clinical trials in USA	18	5
Clinical trials in Spain	17	6
Clinical trials in Canada	16	4
Clinical trials in Israel	15	3
Clinical trials in South Korea	14	4
Clinical trials in Germany	14	6
Clinical trials in Belgium	14	5
Clinical trials in China	13	6
Clinical trials in Taiwan	13	3
Clinical trials in Australia	13	4
Clinical trials in Brazil	12	3
Clinical trials in Portugal	11	3
Clinical trials in UK	11	4
Clinical trials in Turkey	11	3
Clinical trials in Japan	11	5
Clinical trials in Poland	10	3
Clinical trials in Netherlands	9	4
Clinical trials in India	9	2
Clinical trials in Austria	9	2
Clinical trials in Ireland	8	4
Clinical trials in Czechia	7	2
Clinical trials in Switzerland	6	2
Clinical trials in Singapore	5	2
Clinical trials in Sweden	3	1
Clinical trials in Denmark	2	1
Clinical trials in Norway	2	0
EU register (CTIS)	3	—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

Related compounds

Questions about Anastrozole trials

How many clinical trials are testing Anastrozole?

43 current trials in our France, Mexico, Italy, USA, Spain, Canada, Israel, South Korea, Germany, Belgium, China, Taiwan, Australia, Brazil, Portugal, UK, Turkey, Japan, Poland, Netherlands, India, Austria, Ireland, Czechia, Switzerland, Singapore, Sweden, Denmark and Norway registers name Anastrozole (also registered as ICI D1033) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are Anastrozole trials recruiting patients?

Yes. 14 of the 43 trials are recruiting: 8 with sites in France, 3 with sites in Mexico, 6 with sites in Italy, 5 with sites in USA, 6 with sites in Spain, 4 with sites in Canada, 3 with sites in Israel, 4 with sites in South Korea, 6 with sites in Germany, 5 with sites in Belgium, 6 with sites in China, 3 with sites in Taiwan, 4 with sites in Australia, 3 with sites in Brazil, 3 with sites in Portugal, 4 with sites in UK, 3 with sites in Turkey, 5 with sites in Japan, 3 with sites in Poland, 4 with sites in Netherlands, 2 with sites in India, 2 with sites in Austria, 4 with sites in Ireland, 2 with sites in Czechia, 2 with sites in Switzerland, 2 with sites in Singapore, 1 with sites in Sweden and 1 with sites in Denmark. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Anastrozole clinical trials?

Eli Lilly and Company (7), AstraZeneca (6), National Cancer Institute (NCI) (3) and Tolmar Inc (2), among 27 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Anastrozole clinical trials in Ireland?

Yes. 8 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Is Anastrozole licensed in Ireland?

Yes. The HPRA medicines list includes 10 single-substance products containing Anastrozole, for example Agerdex 1 mg film-coated tablets (Viatris Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Anastrozole shortage?

Not in the lists we track: Anastrozole has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Anastrozole works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Anastrozole works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Anastrozole (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.